Results 51 to 60 of about 15,738 (196)

Short‐ and long‐term outcome and quality of life assessment in dogs undergoing transvenous coil embolization of congenital intrahepatic portosystemic shunts

Veterinary Surgery, EarlyView.
Abstract Objective To evaluate short‐ and long‐term outcomes and health‐related quality of life (Hr‐QoL) in dogs with congenital intrahepatic portosystemic shunts (cIHPSS) treated using percutaneous transcatheter embolization (PTCE). Study design Single center retrospective and prospective study. Animals Sixty‐one client‐owned dogs.
Guillaume P. Chanoit, Peter Scott, Kieran Borgeat, Ivan Doran, Vicky Lipscomb, Ed J. Friend   +5 more
wiley   +1 more source

Analysis of the symptom response to esomeprazole 20 mg over days 1–4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials

BMJ Open Gastroenterology, 2019
Background Drug exposure and corresponding antisecretory effects increase over the first 4–5 days of esomeprazole treatment. To date, this effect has not been correlated with symptomatic improvement.
David Peura, Anne Le Moigne, Heather Wassel, Charles Pollack   +3 more
doaj   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Use of Proton Pump Inhibitors as Adjunct Treatment for Triple-Negative Breast Cancers. An Introductory Study

Journal of Pharmacy & Pharmaceutical Sciences, 2014
PURPOSE: Triple negative breast cancers (estrogen, progesterone and human epidermal growth factor 2 (HER2) receptor-negative) are among the most aggressive forms of cancers with limited treatment options. Doxorubicin is one of the agents found in many of
Wayne Goh, Inna Sleptsova-Freidrich, Nenad Petrovic   +2 more
doaj   +1 more source

Post vaccinal temporary sensorineural hearing loss [PDF]

, 2018
In our systematic research we identified four studies concerning the onset of neurological adverse events following vaccination and two excluding this association.
De Cesare, Donato Pompeo, De Marco, Federica, Di Folco, Francesco, Di Luca, Natale Mario, Massoni, Francesco, Ricci, Serafino, Sacco, Carmina, Tomei, Francesco, Tomei, Gianfranco   +8 more
core   +1 more source

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

Contact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli, Khadija Mansour, Ghada Jaouahdou, Manel Ben Belgacem, Yosra Soua, Nadia Ben Fredj, Jameleddine Zili, Haifa Ben Romdhane, Karim Aouam   +8 more
wiley   +1 more source

Still a dilemma! Are vonoprazan and esomeprazole attenuating the antiplatelet function of clopidogrel when taken concomitantly? A systematic review and meta-analysis

The Egyptian Journal of Internal Medicine
Objective CYP2C19 metabolizes all three drugs—esomeprazole, vonoprazan, and clopidogrel—so it is mostly responsible for their drug interactions. Is this clinically true or just theoretical?
Eman Youssef, Aliaa Gamal, Hagar Youssef
doaj   +1 more source

Antibiotic Cocktail Exacerbates Esomeprazole-Induced Intestinal Dysmotility While Ameliorating Gastric Dyspepsia in Mice

Antibiotics
Background/Objectives: Esomeprazole, a proton pump inhibitor (PPI), is commonly prescribed for gastric-acid-related disorders but has been associated with impaired gastrointestinal (GI) motility with long-term use.
Jing-Hua Wang, Song-Yi Han, Kyungjae Lee, Uijeong Han, Si-Kyung Cho, Hojun Kim   +5 more
doaj   +1 more source

Not Only Enteropathy: The Overlooked “Gastric Side” of Olmesartan

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Several medications can be associated with gastrointestinal adverse effects. Olmesartan has been linked to a broad spectrum of gastrointestinal injuries. Although sprue‐like enteropathy is well known, less common involvements such as gastropathy can be equally debilitating.
Cecilia Lina Pugliano, Stefania Piccirelli, Denise Bianchi, Clarissa Ferrari, Cristiano Spada, Paola Cesaro   +5 more
wiley   +1 more source

The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study

Gut and Liver
Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has beneficial effects on acid-related disorders such as gastroesophageal reflux and peptic ulcer diseases. This study aimed to validate the effect of tegoprazan on endoscopic
Byung-Wook Kim, Jong Jae Park, Hee Seok Moon, Wan Sik Lee, Ki-Nam Shim, Gwang Ho Baik, Yun Jeong Lim, Hang Lak Lee, Young Hoon Youn, Jun Chul Park, In-Kyung Sung, Hyunsoo Chung, Jeong Seop Moon, Gwang Ha Kim, Su Jin Hong, Hyuk Soon Choi   +15 more
doaj   +1 more source